Ibezapolstat cured all 10 patients of their Clostridioides difficile infections and prevented recurrence for at least 30 days.
List view / Grid view
Researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the FDA to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.
A new study found that infections caused by the drug resistant bacteria - methicillin-resistant Staphylococcus aureus, known as MRSA - are no more expensive to treat than MSSA, the methicillin-susceptible version of the same bacteria.
A new antibiotic, produced by bacteria found on a species of African ant, is very potent against antibiotic-resistant ‘superbugs’ like MRSA according to scientists.
5 January 2016 | By Victoria White
The minimal increase over the next decade will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin)...
9 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has accepted Aridis Pharmaceuticals’ Investigational New Drug (IND) application for AR-301 (Salvecin)...
Changing the way we combat bacterial infections: Dutch biotech Micreos launches first bacteria-killing enzyme for human use against MRSA
5 November 2014 | By Micreos
Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA)...
12 March 2013 | By Department of Health
Chief Medical Officer says global action is needed otherwise in 20 years we could see any one of us dying following minor surgery...